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The growth factor midkine (MK) has been reported to bind heparan sulfate and nucleolin, two components of the cell
surface implicated in the attachment of HIV-1 particles. Here we show that synthetic and recombinant preparations of MK
inhibit in a dose-dependent manner infection of cells by T-lymphocyte- and macrophage-tropic HIV-1 isolates. The binding of
labeled MK to cells is prevented by excess unlabeled MK or by the anti-HIV pseudopeptide HB-19 that blocks HIV entry by
forming a stable complex with the cell-surface-expressed nucleolin. MK mRNA is systematically expressed in adult
peripheral blood lymphocytes from healthy donors, while its expression becomes markedly but transiently increased upon
in vitro treatment of lymphocytes with IL-2 or IFN-g and activation of T-lymphocytes by PHA or antibodies specific to
CD3/CD28. In MK-producing lymphocytes, MK is detectable at the cell surface where it colocalizes with the surface-
expressed nucleolin. Finally, by using MK-producing CD41 and CD42 cell clones we show that HIV infection in cell cultures
could be inhibited in both an autocrine and a paracrine manner. The potent and distinct anti-HIV action of MK along with its
enhanced expression in lymphocytes by various physiological stimuli suggests that MK is a cytokine that could be implicated
in HIV-induced pathogenesis. © 2001 Academic Press
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The human immunodeficiency virus (HIV) infects target
cells by the capacity of its envelope glycoprotein gp120-
gp41 complex to attach cells and induce the fusion of
virus to cell membranes, a process which leads to virus
entry. The receptor complex essential for HIV entry con-
sists of the CD4 molecule and at least one of the mem-
bers of the chemokine receptor family: CCR5 is the major
coreceptor for macrophage-tropic HIV-1 isolates (R5),
whereas that for T-lymphocyte-tropic isolates (X4) is
CXCR4 (Berger, 1997; Wyatt and Sodroski, 1998). The
external envelope glycoprotein gp120 contains three ma-
jor targets for the action of neutralizing antibodies, the
CD4-binding domain, the third hypervariable domain re-
ferred to as the V3 loop, and a conserved region between
the V1/V2 and the V3 loop that appears to be responsible
for the binding of R5/X4 virus to their respective chemo-
kine receptor (Rizzuto et al., 1998). Depending on the cell
type studied, the inhibition of HIV entry by blocking CD4
does not necessarily affect HIV attachment (Mondor et
al., 1998; Valenzuela et al., 1997). Similarly, as chemokine
receptors become recruited following binding of HIV to
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248CD4, chemokines and chemokine-receptor inhibitors
block HIV entry in the absence of any apparent effect on
the virus particle attachment to cells (Nisole et al., 1999,
2000; Oravecz et al., 1996). Contrary to the viral entry
rocess, the attachment of HIV particles to cells can
ccur even independently of CD4 through coordinated
nteractions with cell-surface-expressed heparan sulfate
roteoglycans and V3 loop-binding proteins (Callebaut et
l., 1998a; Mondor et al., 1998; Nisole et al., 1999; Rode-
iquez et al., 1995; Saphire et al., 1999; Ugolini et al., 1999;
Valenzuela et al., 1997). Consequently, targeting each
one of these components could result in the inhibition of
HIV attachment. Indeed, HIV attachment could be
blocked either by the fibroblast growth factor 2 (FGF-2)
that binds heparan sulfate proteoglycans or by the anti-
HIV pseudopeptide HB-19 which binds nucleolin, a cell-
surface-expressed protein identified to bind the V3 loop
(Nisole et al., 1999). The fact that HIV attachment could
be inhibited by two different agents which do not com-
pete suggests that attachment is achieved by the coor-
dination of at least two events implicating on the one
hand heparan sulfate proteoglycans and on the other
hand V3 loop-binding protein nucleolin (Nisole et al.,
1999). Recent evidence suggests that interaction of HIV
particles with heparan sulfate proteoglycans might be
mediated by cyclophilin A, i.e., a cellular protein which
becomes incorporated into the viral membrane during
HIV production (Saphire et al., 1999).In the search for natural ligands of nucleolin and
heparan sulfate proteoglycans that exhibit a potential
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249INHIBITION OF HIV ATTACHMENT IN MIDKINE-TREATED CELLSinhibitory activity against HIV infection, we came across
three heparin-binding growth factors: FGF-2 (Nisole et
al., 1999), midkine (MK; the results herein), and pleiotro-
phin (PTN, unpublished results). The mature MK protein
without its signal peptide is a 13-kDa growth factor which
was discovered as a heparin-binding protein. It shares
45% sequence identity with PTN also referred to as
heparin-binding growth-associated molecule (HB-GAM).
Despite their striking structural homology and the con-
servation of their net positive charge, MK and PTN ap-
pear to have distinct receptors or receptor complexes
(Iwasaki et al., 1997; Kurtz et al., 1995; Muramatsu, 1994).
he PTN receptor is most probably the proteoglycan
yndecan-3 (Raulo et al., 1994) and in this respect, PTN
an compete with FGF-2 which uses heparan sulfate
roteoglycans as low affinity receptors (Kurtz et al.,
995). On the other hand, although the binding of MK to
eparan sulfate and chondroitin sulfate proteoglycans
ould be clearly demonstrated using purified and soluble
omponents (Kurosawa et al., 2000; Zou et al., 2000), the
ell-surface receptor for MK is not yet identified. For
haracterizing the MK receptor, nucleolin has been iso-
ated by purification of crude cell extracts using a MK-
ffinity matrix column (Take et al., 1994). MK and PTN
epresent a distinct family of secreted growth factors that
re functional in differentiation of cells of different origin
rom early embryogenesis to malignant transformation
Iwasaki et al., 1997; Kurtz et al., 1995; Muramatsu, 1994).
hey are expressed during embryogenesis with an ex-
ression pattern suggesting functions in neurogenesis,
ell migration, secondary organogenetic induction, and
esoderm-epithelial interaction.
Several reports have shown that the expression of MK
nd PTN is upregulated during pathological situations,
hereas their expression in the normal adult tissue has
een considered to be repressed (Iwasaki et al., 1997;
urtz et al., 1995; Muramatsu, 1994). Nevertheless, here
we show that MK but not PTN is expressed constitutively
in vivo in healthy individuals since MK mRNA was de-
tectable systematically in peripheral blood lymphocytes
(PBL). In addition, MK but not PTN mRNA was induced
transiently upon in vitro activation of T-lymphocytes with
PHA or with anti-CD3/anti-CD28 antibodies. MK expres-
sion is also induced upon stimulation through the CD28
receptor alone and treatment with IL-2 or IFN-g. The MK
rotein becomes detectable at the cell surface and in the
ucleolus of activated lymphocytes as revealed by laser
canning confocal immunofluorescence microscopy.
onsequently, our results show that MK is a cytokine
hich is expressed in healthy adults contrary to what
as been considered before. We show that MK is a
otent inhibitor of HIV infection in both primary T-lym-
hocytes and in the HeLa-CD41 experimental model that
was used here. The anti-HIV action of MK is the conse-
quence of inhibition of HIV attachment in MK-pretreated
cells in a dose-dependent manner. HIV attachment is
w
Beven inhibited in MK-treated cells not expressing the
CD4 receptor, thus indicating that an early event in the
HIV attachment process is affected. This inhibitory action
of MK against HIV infection, along with the enhanced
expression of MK mRNA in response to various physio-
logical stimuli, points out that MK could be implicated in
HIV-induced pathogenesis. Consistent with this, we
show that CD41 CEM T-cell clones expressing recombi-
nant MK resist HIV infection by the inhibition of virion
attachment to cells. Moreover, MK-producing CD42 cell
clones can transmit protection of CD41 bystander cells
against HIV infection, thus demonstrating the transfer of
MK from CD42 to CD41 cells. Previously, several cyto-
ines, such as chemokines, interferons, IL-2, and IL-16,
ave been shown to affect directly or indirectly HIV
nfection (Berger, 1997; Francis et al., 1992; Kutza et al.,
998; Manetti et al., 1996; Zhow et al., 1997). Our results
resented here demonstrate for the first time that MK
nhibits HIV infection by a distinct anti-viral mechanism,
nd thus it could be implicated along with other cyto-
ines in the evolution of HIV infection.
RESULTS AND DISCUSSION
nhibition of T-lymphocyte- and macrophage-tropic
IV-1 isolates in MK-treated cells
The inhibitory effect of MK on X4 and R5 HIV-1 entry
nd infection was first investigated in the experimental
odel of HeLa-CD4-LTR-lacZ cells expressing constitu-
ively CXCR4 (HeLa P4 cells) or in addition expressing
ecombinant CCR5 (HeLa P4-C5 cells). HIV entry and
eplication in these cells result in Tat-mediated activation
f the HIV LTR, leading to the expression of the lacZ
ene. Consequently, the b-galactosidase activity could
e measured in cell extracts to monitor HIV entry into
ells. The value of b-galactosidase activity obtained in
the presence of AZT is considered as the background
value in each experiment. The CD4-mediated entry was
also monitored for each virus type by the anti-CD4 mAb
CB-T4 that reacts with the gp120-binding site in CD4
(Valenzuela et al., 1997). The nucleolin-binding pseu-
dopeptide HB-19 was used to illustrate an inhibitory
effect on HIV entry (Callebaut et al., 1998a; Nisole et al.,
2000; Seddiki et al., 1999), whereas the corresponding
control pseudopeptide HBP8-I expressing an equivalent
positive charge was used as an appropriate control (Ni-
sole et al., 2000). As we had shown previously, HB-19
inhibited the entry of both X4 HIV-1 LAI and R5 HIV-1
Ba-L isolate whereas the control peptide had no signifi-
cant effect. On the other hand, the CXCR4-binding TW70
peptide inhibited X4 HIV-1 LAI but not R5 HIV-1 Ba-L
entry, as it was reported before (Murakami et al., 1997;
Nisole et al., 1999, 2000). Finally, heparin at 1–5 mg/ml
esulted in more than 90% inhibition of HIV-1 LAI entry
hereas no significant effect was observed on HIV-1
a-L (Figs. 1A and B). Heparin could block the attach-
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250 CALLEBAUT ET AL.ment of HIV-1 LAI particles presumably by its capacity to
bind basic residues in gp120 (Callebaut et al., 1998a;
ondor et al., 1998; Nisole et al., 1999; Roderiquez et al.,
995; Saphire et al., 1999; Ugolini et al., 1999; Valenzuela
t al., 1997) or to bind cyclophilin A incorporated in the
embrane of a X4 HIV-1 isolate (Saphire et al., 1999).
In these well-characterized HeLa experimental mod-
ls, two commercially available preparations of human
K, either synthetic (MKS) or recombinant (MKB) were
hown to inhibit the X4 HIV-1 LAI entry with an IC50 value
f 25 nM for MKB and 100 nM for MKS. More than 90%
inhibition occurred at 125 nM MKB and 250 nM MKS (Fig.
FIG. 1. The inhibition of HIV infection in MK-treated cells is specific
different cell clones, HeLa P4 and HeLa P4-C5 expressing endogeno
molecules, were treated (incubation at 37°C, 30 min) with AZT (5 mM
ucleolin-binding HB-19 peptide (each at 1 mM), the control peptide
oncentrations as indicated, before infection with the various viral
seudotypes with either the VSV or MoMLV-envelope glycoproteins. A
0 min with heparin (at 1, 5, and 10 mg/ml) before addition to the cell
ell extracts directly in order to monitor HIV entry as described befo
b-galactosidase activity in the absence of addition of HIV. The mean 61A). The slightly lower activity of MKS compared to MKB
was most probably due to differences which might existbetween the chemically synthesized molecule and the
recombinant protein generated by the bacterial system.
MKS also inhibited entry of the R5 HIV-1 Ba-L and JR-CSF
solates, with IC50 values of 125 and 250 nM, respectively
(Figs. 1B, and C). Interestingly, MK had no significant
effect on the entry of R5 HIV-1 ADA isolate (Fig. 1D)
which previously was found to be the only HIV-1 strain
resistant to the anti-HIV effect of HB-19 among various
X4 and R5 HIV isolates tested (Nisole et al., 1999, 2000).
In this respect, it is of interest to note that enhancement
rather than inhibition of infection by HIV-1 ADA virus has
also been reported upon treatment with b-chemokines
viral entry process mediated by the HIV-envelope glycoproteins. Two
R4 and respectively recombinant human CD4 or human CD4/CCR5
CD4 mAb CB-T4 (a-CD4; 5 mg/ml), the CXCR4-binding TW70 and the
(5 mM), and MK(S) (synthetic MK) or MK(B) (recombinant MK) at nM
, X4 HIV-1 LAI, R5 HIV-1 Ba-L, JR-CSF, and HIV-1 ADA, and HIV-1
rin acts on HIV particles, the different HIV isolates were preincubated
. At 48 h postinfection, the b-galactosidase activity was measured in
ole et al., 2000). The histogram No HIV represents the background
f triplicate samples is shown.to the
us CXC
), anti-
HBP8-I
isolates
s hepa
cultures(Gordon et al., 1999). Furthermore, HIV-1 ADA is sensitive
to the inhibitory effect of heparin (Fig. 1D), like the X4
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251INHIBITION OF HIV ATTACHMENT IN MIDKINE-TREATED CELLSHIV-1 isolates such as HIV-1 LAI (Fig. 1A), whereas other
R5 isolates such as HIV-1 Ba-L are relatively resistant
(Fig. 1B). Thus the HIV-1 ADA isolate behaves somewhat
differently from the known R5 HIV-1 isolates. Whatever
the case, the HIV-1 ADA isolate could be used as a
control virus to demonstrate that the antiviral effect of MK
and HB-19 on the sensitive X4 and R5 isolates can not be
argued to be the consequence of a potential toxic effect
on cells (Fig. 1) (Nisole et al., 1999, 2000).
In order to confirm the specificity of MK with respect to
the HIV-envelope glycoprotein-mediated viral entry pro-
cess, we investigated its inhibitory effect on infection by
the HIV-1 pseudotype with envelope glycoproteins of
vesicular stomatitis virus (VSV) or Moloney murine leu-
kemia virus (MoMLV). Infection by these pseudotyped
HIV preparations was inhibited by AZT but not by the
anti-CD4 mAb CB-T4, since viral binding and entry are
mediated by the pseudotyped viral envelope glycopro-
teins. Interestingly, MK (Figs. 1E and F) as HB-19 (Calle-
baut et al., 1998a; Nisole et al., 1999, 2000) exerted no
ignificant effect on the pseudotyped HIV, thus pointing
ut that the inhibitory effect of these molecules is medi-
ted on the entry process via the native HIV-envelope
lycoproteins.
K is a powerful inhibitor of HIV infection in T
ymphocytes
PHA-activated peripheral blood lymphocytes were
reated with different doses of MKS before infection with
the HIV-1 UG029A primary isolate. In this particular ex-
periment, MK was added twice in the cell culture during
the kinetics of virus infection: first, before addition of HIV
and, second, on Day 3 of infection. Without any treat-
ment, a significant level of virus production was ob-
served on the 6th day of infection with a first peak on Day
8 and thereafter a decrease by Day 12, at which time the
cells most probably became chronically infected since
they kept on producing HIV. MK treatment caused a
dramatic inhibition of virus infection and a significant
delay on the onset of virus production (Fig. 2). At 250 nM
MK, low levels of virus production were detectable only
on Day 6 of infection, whereas at 500 nM MK, no virus
production was detectable up to the 14th day of infection.
Late in the kinetics of infection, HIV production became
detectable in the MK-treated cultures, though its level
remained significantly lower compared to that of the
control culture. In order to measure the IC50 of MK on HIV
infection of T-lymphocytes, treatment of MK was done
only during a 30-min period of preincubation of cells,
before removal of MK-containing medium and addition of
virus. Under such experimental conditions in which MK
was added only once before HIV, the IC50 of MKS on HIV-1
UG029A and BRO25C primary isolates, at the peak of
virus production, was estimated to be 250 nM (not
shown).It should be noted that under similar experimental
conditions used for the infection of PBL in Fig. 2, treat-
ment of activated T-lymphocytes with 500 nM MKS for 3
days had no apparent effect on the viability of cells
measured as described before (Callebaut et al., 1996).
Furthermore, no apparent effect was observed in MK-
treated cell cultures for surface expression of CD4,
CXCR4, and CCR5 as monitored by FACS analysis using
specific monoclonal antibodies (not shown; experimental
procedures were as described in (Seddiki et al., 1999)).
Mechanism of the anti-HIV action of MK
MK is an efficient inhibitor of HIV infection when
added to cells before virus, whereas when added a
few hours after virus entry then it exerts no significant
effect (data not shown). This points out that the anti-
HIV action of MK is at an early phase in the HIV
infectious cycle, as is the case with the HB-19 pseu-
dopeptide (Callebaut et al., 1998a; Nisole et al., 1999,
2000). The effect of MK on the attachment of HIV-1 LAI
and Ba-L particles was then investigated in two types
of cells: permissive HeLa P4-C5 cells expressing CD4,
CXCR4, and CCR5, and nonpermissive HeLa cells
which express only CXCR4. In order to avoid any viral
entry and endocytosis, these experiments were car-
ried out at 4°C. Under such experimental conditions,
most of the virus associated with cells was shown to
FIG. 2. MK inhibits HIV infection of in primary T-lymphocytes. PHA-
activated lymphocytes (at 7 days post-PHA addition) were treated with
250 and 500 nM of MKS for 15 min before the addition of the primary
HIV-1 UG029A isolate. Virus inoculum was removed by centrifugation
after 1 h and the cells were cultured in fresh medium (Materials and
Methods). Culture supernatant was monitored for the production of HIV
by measuring the concentration of the HIV major core protein p24
(ordinate) at different days up to Day 21 postinfection (abscissa). MK
was added only at the beginning and at Day 3, while cell passage was
every 3 or 4 days by removing half of the culture medium and adding
fresh medium. Each histogram represents the mean of duplicate sam-
ples.be on the cell surface, since its recovery was reduced
by more than 90% after treatment of cells with trypsin.
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252 CALLEBAUT ET AL.Furthermore, consistent with our previous reports (Ni-
sole et al., 1999), the neutralizing mAb specific to the
equence of the V3 loop of HIV-1 LAI inhibited signif-
cantly the attachment of this virus in both CD41 and
CD42 cells, thus pointing out that the attachment pro-
cess was indeed mediated by the HIV-envelope gly-
coprotein gp120. In both CD41 and CD42 HeLa cell
ines studied, MK inhibited drastically in a dose-de-
endent manner the attachment of HIV-1 LAI and Ba-L
o cells (Fig. 3). The observation that MK inhibited HIV
ttachment to CD42 cells indicates that the mecha-
ism of action of MK is independent of HIV interaction
ith CD4. In addition, these results point out that the
echanism of action of MK is at a very early step in
he HIV entry process. As we had shown previously
Nisole et al., 2000), HB-19 inhibited the attachment of
IV-1 LAI and Ba-L to CD41 and CD42 cells (Fig. 3).
However, the CXCR4-specific anti-HIV peptide TW70
had no effect on the attachment of HIV-1 LAI (Fig. 3),
although as it was expected, it inhibited virus entry in
the CD41 HeLa cells (Fig. 1A).
In order to visualize inhibition of HIV particle attach-
ent to MK-treated cells, staining of the cell-surface-
ttached HIV was carried out by antibody-dependent
FIG. 3. MK inhibits the attachment of HIV particles to CD41/permissiv
anel) were treated with MK(S) at different nM concentrations (as in
orresponding control pseudopeptide HBP8-I (2 mM), and the CXCR4-bi
or 30 min at 37°C in the absence or presence of the stated reagents be
IV-1 LAI or HIV-1 Ba-L in fresh culture medium. HIV attachment to ce
ackground after trypsin digestion of cells. In the sample anti-V3, HIV
efore addition to cells. The 100% binding corresponds to the amoun
ignificant difference in the amount of HIV associated to control CD41ross-linking of the HIV surface glycoprotein, gp120, still
emaining accessible on HIV particles following virusttachment to cells. For this purpose, we used anti-V3
oop mAbs N11-20 and 110-4 which are known to interact
ith the V3 loop on HIV particles and block virus attach-
ent to CD41 and CD42 cells (Callebaut et al., 1998a;
Nisole et al., 1999; Valenzuela et al., 1997). However,
when such antibodies are added after the attachment of
HIV to the cell surface, they still can bind virus by inter-
acting with gp120 present on regions of HIV particles not
interacting with the plasma membrane. Consequently, by
this procedure we could demonstrate the presence of
HIV particles attached on the surface of control HIV-1
LAI-infected cells (Fig. 4A). No signal was observed
intracellularly when the scan was carried out toward the
middle section of cells, thus indicating that the signal
was found only at the cell surface (not shown). In con-
trast to control HIV-infected cells, the surface gp120
signal was drastically reduced in MK-treated cells (Fig.
4B), in accord with the inhibition of HIV attachment re-
sults shown in Fig. 3. Similarly, only a faint signal was
observed when HIV particles were preincubated with
mAb N11-20 or 110-4 before the addition of virus/anti-
body mixture to cells (not shown), consistent with the
capacity of these antibodies to block HIV attachment
CD42/nonpermissive cells. HeLa P4-C5 (left panel) or HeLa cells (right
). Other reagents were the nucleolin-binding HB-19 (1 mM) and its
W70 peptide (1 mM). Cell monolayers (0.5 3 106 cells) were incubated
moval of the medium containing the different reagents and the addition
carried out at 4°C (Materials and Methods). Sample trypsin gives the
reparation was incubated (37°C, 30 min) with mAb N11/20 (5 mg/ml)
V associated to cells not pretreated with any reagent. There was no
D42 cells.e and
dicated
nding T
fore re
lls was
-1 LAI p(Callebaut et al., 1998a; Nisole et al., 1999; Valenzuela et
al., 1997).
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253INHIBITION OF HIV ATTACHMENT IN MIDKINE-TREATED CELLSThe binding of MK to cells
The interaction of 125I-labeled MK with the cell surface
was investigated at room temperature (20°C) to avoid
internalization into cells. Most of the 125I-labeled MK was
found to be localized on the cell surface since trypsin
treatment of cells eliminated more than 95% of bound
MK. Furthermore, this binding appeared to be somewhat
specific since it was reduced in a dose-dependent man-
ner by excess unlabeled MK (Fig. 5). Furthermore, the
nucleolin-binding HB-19 pseudopeptide drastically inhib-
ited the binding of 125I-labeled MK to cells whereas the
ontrol peptides CP-1 and HBP8-I had no effect (Fig. 5).
he IC50 values for the inhibition of HIV-1 LAI infection in
he HeLa P4 cells by MKB (Fig. 1A) and HB-19 (Nisole et
l., 2000) are 25 and 100 nM, thus suggesting that the
ffinity of MKB to bind cells is at least 4-fold higher than
that of HB-19, as far as the inhibition of HIV infection is
concerned. Despite this, HB-19 was efficient in prevent-
ing the binding of MK to cells. This could probably be due
to the capacity of HB-19 to bind cells in an irreversible
manner under physiological conditions (Nisole et al.,
1999). Interestingly, the binding of the 125I-labeled MK to
cells was significantly reduced by HIV-1 LAI but not HIV-1
FIG. 4. Lack of association of HIV particles on the surface of MK-treat
edium in the absence (A) or presence of MKB (0.1 mM; B) for 30 m
emperature for 1 h. Cell monolayers were then washed with PBS to elim
nd mAb 110-4 (20 mg/ml) for 1 h at room temperature in order to reve
virus attachment. Cells were then fixed with 3.7% PFA before addition
represent the upper surface of cells whereas the phase contrasts sho
A similar inhibition of HIV attachment was observed in HeLa P4 cellsADA particles (Fig. 5), in accord with the sensitivity and
resistance of HIV-1 LAI and HIV-1 ADA to the anti-HIVinhibitory effect of MK, respectively (Figs. 1A and D).
Such inhibition of MK binding by HIV-1 LAI particles
might be accounted by the interaction of MK and HIV
with common cell surface component(s). It is worthwhile
here to note that the HIV-1 LAI but not HIV-1 ADA parti-
cles are capable of preventing the specific binding of the
HB-19 pseudopeptide to surface nucleolin (Nisole et al.,
1999).
As the HB-19 pseudopeptide binds cells specifically
and forms a stable complex with the cell-surface-ex-
pressed nucleolin (Callebaut et al., 1998a, 1997; Nisole et
al., 1999), the inhibition of MK binding by HB-19 (Fig. 5)
favors the suggestion that nucleolin could be implicated
in the MK-binding process. At this stage, we cannot
eliminate the possibility that MK also interacts with the
cell-surface-expressed heparan sulfate proteoglycans.
However, it should be emphasized that recent studies
illustrating the affinity of MK to heparan or chondroitin
sulfate have been carried out with purified proteoglycans
and glycans but not using intact cells (Kurosawa et al.,
2000; Zou et al., 2000). The lack of correlation between
the anti-HIV inhibitory effect of MK and heparin on vari-
ous HIV isolates (Figs. 1A, B, and D) suggests that
s. HeLa P4 cells (plated in glass slides) were incubated in fresh culture
7°C before addition of HIV-1 LAI and further incubation but at room
unbound HIV particles before incubation in medium containing 1% FCS
gp120 on the surface of HIV particles still remaining accessible after
t FITC-labeled anti-mouse antibodies. The immunofluorescent scans
s of the middle cross section of the respective cell monolayers. Note.
ted with 0.5 mM MKS or 1 mM HB-19 (not shown).ed cell
in at 3
inate
al HIV
of goaheparan or chondroitin sulfate can not be considered as
one of the main targets of MK for its anti-HIV action.
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254 CALLEBAUT ET AL.Accordingly, preliminary results have shown that MK can
bind to Chinese hamster ovary cells deficient in heparan
and chondroitin sulfate proteoglycan (Esko et al., 1988) in
which nucleolin is still expressed at the cell surface.
Furthermore, MK binding to such proteoglycan-deficient
cells is inhibited by the HB-19 pseudopeptide (unpub-
lished data).
The increased production of MK in activated
lymphocytes
The expression of MK was systematically observed by
the detection of its mRNA in PHA-activated PBL prepa-
rations from healthy donors. A typical experiment is pre-
sented showing the level of MK mRNA expression before
and after PHA stimulation of PBL (Fig. 6A). The low level
of MK mRNA which was detectable in total PBL recov-
ered from the donor became undetectable after 24 h in
culture (Fig. 6A, lanes S and 0, respectively). At 2 to 4
days post-PHA activation, however, the MK mRNA ex-
pression was significantly increased. The kinetics of MK
RNA expression indicated that there was a 24-h delay in
MK expression compared to that of the well-known PHA-
induced cytokine, IFN-g (Fig. 6A). Both MK and IFN-g
induction were transient as they were followed by a
FIG. 5. The binding of 125I-labeled MK to cells is inhibited by unla-
eled MK or HB-19. HeLa P4 cell monolayers were preincubated at
oom temperature for 20 min in fresh culture medium in the absence
the sample control) or presence of MKB and HB-19 (at 2, 4, and 8 mM)
or control peptides CP-1 (50 mM) and HBP8-I (8 mM) before addition of
125I-labeled MKB. To investigate the effect of HIV particles on the
binding of MK, cells in culture medium were preincubated (4°C, 30 min)
with HIV-1 LAI or HIV-1 ADA-M particles, respectively, at a dose cor-
responding to 0.2 mg/ml of p24 (as described in Nisole et al., 1999).
fter the preincubation, all samples were further incubated with the
125I-labeled MK (80 nM) at room temperature for 30 min. Cells were then
washed extensively with the culture medium before the preparation of
nuclear free extracts and quantification of the radioactivity. The histo-
grams present the mean of duplicate samples.marked decline, thus suggesting the existence of a reg-
ulatory mechanism which is commonly observed in theinduction kinetics of cytokines and chemokines (Ye and
Young, 1997). There is a retinoic acid-responsive element
in the MK gene promoter (Muramatsu, 1994). Conse-
quently, as a control for MK induction in PBL we showed
that MK mRNA was increased in response to retinoic
acid treatment (not shown). The 432-bp cDNA generated
by RT-PCR using the MK-specific primers was cloned,
and its nucleotide sequence revealed that it indeed cor-
responds to the sequence encoding the full-length hu-
man MK containing 143 amino acids, the first 22 residues
of which represent the signal peptide.
In order to investigate MK expression under physio-
logical conditions of T cell activation, PBL were stimu-
lated through the CD3 and CD28 receptors by specific
monoclonal antibodies (Li et al., 1999). Such CD3/CD28
stimulation leads to the induction of MK mRNA which
was transiently increased and then was followed by a
marked reduction (Fig. 6B). In a series of experiments
(Figs. 6C and D), we then demonstrated that stimulation
through CD28 was sufficient for the induction of MK,
whereas stimulation through CD3 had no effect. Interest-
ingly, IL-2 and IFN-g treatment alone was also effective
for the induction of MK mRNA. Despite slight variations
in the kinetics of MK mRNA induction observed in differ-
ent PBL preparations, the maximum increase of MK was
reproducibly observed 2 to 3 days following the addition
of mAb anti-CD28, IL-2, or IFN-g (Fig. 6C). Among these
three reagents, only IL-2 treatment resulted in the induc-
tion of IFN-g mRNA (Fig. 6D). This differential induction of
MK and IFN-g might be the consequence of variations in
response to individual reagents observed in different cell
types or subtypes existing in the mixed population of
lymphocytes. The expression of the nucleolin mRNA, like
the housekeeping gene GAPDH mRNA, was enhanced
in response to stimulation by the different reagents (Figs.
6C and D). Increased nucleolin expression following IL-2
treatment has also been reported previously (Herblot et
al., 1999).
The expression of MK was systematically detectable
in PBL recovered from healthy individuals (Fig. 6E),
though at several-fold lower levels compared to those
occurring after in vitro stimulation. The level of MK mRNA
xpressed in vivo became undetectable 24 h following
ncubation of lymphocytes in the absence of any stimu-
ation (Figs. 6A, B, C, lanes 0). The mRNA of PTN and
FN-g were not expressed in vivo whereas that of
GAPDH and nucleolin were expressed (Fig. 6E). It should
be noted that the type of lymphocytes expressing MK in
vivo, and following in vitro stimulation in respect to dif-
ferent reagents, might be different. Nevertheless, MK
produced by one cell type might have the potential ca-
pacity to interact with bystander cells of different types.
In order to avoid any interference on the HIV infection by
MK produced during activation of PBL, HIV infections
were routinely carried out at 6 to 7 days post-PHA treat-
ment when the MK mRNA levels were reduced. HIV
DT-PCR
255INHIBITION OF HIV ATTACHMENT IN MIDKINE-TREATED CELLSinfection of PBL at 4–5 days post-PHA activation was not
very efficient, since the kinetics of virus production was
delayed by several days compared to infection of PBL at
6–7 days post-PHA activation. With the same virus stock
and PBL preparations, the peak of HIV production oc-
curred consistently at 6–8 and 10–14 days postinfection
in PBL cultures which were infected on Days 7 and 4 of
PHA activation, respectively.
Recovery of MK from culture supernatants of activated
PBL required large amounts of supernatants, most prob-
ably due to the rapid binding of secreted MK to the
surface of cells. Indeed, by confocal immunofluores-
cence microscopy a significant amount of endogenous
MK was observed at the cell membrane of PBL on the
third day of PHA activation compared to the correspond-
FIG. 6. Expression of MK mRNA in peripheral blood lymphocytes. (A
S represents the ex vivo expression, whereas lanes 1, 2, 3, 4, 6, and
represents the sample at 24 h after culturing of the freshly isolated PBL
is induced transiently in PBL stimulated by mAb anti-CD3 and anti-CD
represent the expression at different days post-CD3/CD28 stimulation
culturing the freshly isolated PBL (lane 0) and posttreatment with IL-2
anti-CD28 (10 ng/ml; at Days 2 and 4), and mAb anti-CD3 (10 ng/ml; a
mRNA were determined after 24 h of culturing the freshly isolated PBL (
mAb anti-CD28 (10 ng/ml), mAbs anti-CD3 1 anti-CD28 (each at 10 ng/m
obtained using a PTN-expressing plasmid (lane C). (E) MK mRNA is sy
4). The rectangle with an asterisk shows an increased exposure of the
obtained using the PTN-expressing plasmid and cDNA from IL-2-stim
donors were used in the experiments presented in A to D. The size of R
368, and 835 nucleotides, respectively.ing cells before activation (Figs. 7A and B). The MK
signal at the periphery of activated lymphocytes wasmarkedly reduced on Day 7 (Fig. 7C) in accord with the
transient induction of the MK mRNA level during PHA
activation of PBL (Fig. 6A). In contrast to the detection of
surface MK, nucleolin was detectable on the surface of
PBL before activation and its expression was increased
and remained elevated in PHA-activated PBL (Figs. 7A to
C). Furthermore, PBL at 7 days postactivation were able
to bind the synthetic MK as revealed by a strong MK
staining at the cell surface (Fig. 7D). Interestingly, the
surface MK staining, either endogenous or exogenous,
colocalized with the nucleolin staining at the cell surface
(Figs. 7B and D). Besides the cell surface, the endog-
enously produced MK was also detectable in the nucle-
olus (Fig. 7E) which has also been reported in MK-
producing mouse hemangioma cells (Take et al., 1994).
d IFN-g mRNA are induced transiently in PBL activated by PHA. Lane
esent the expression at different days post-PHA stimulation. Lane 0
as added on Day 0 whereas TCGF was added on Day 3. (B) MK mRNA
h at 10 ng/ml). Lane 0 is as in section A, whereas lanes 2, 4, 6, and 8
e relative amounts of MK and GAPDH were determined after 24 h of
nits/ml; at Days 1 and 3), IFN-g (500 units/ml; at Days 1 and 3), mAb
). (D) The relative amounts of MK, GAPDH, IFN-g, nucleolin, and PTN
and in PBL at 3 days posttreatment with PHA, mAb anti-CD3 (10 ng/ml),
(150 units/ml), and IFN-g (500 units/ml). A positive control for PTN was
ically detected in PBL isolated from healthy donors (donors D1, D2, D3,
responding to the MK results. Positive controls for PTN and IFN-g were
PBL (lanes C), respectively. Different PBL preparations from healthy
product for MK, GAPDH, IFN-g, PTN, and nucleolin was 432, 983, 433,) MK an
8 repr
. PHA w
28 (eac
. (C) Th
(150 u
t Day 4
lane 0)
l), IL-2
stemat
gel cor
ulatedAs it was the case at the cell surface, the MK signal in
the nucleoli colocalized with that of nucleolin (Fig. 7E). In
ending p
ents (no
256 CALLEBAUT ET AL.view of the affinity of MK to bind nucleolin, Take et al.
have suggested that nucleolin could participate in the
nuclear translocation of MK (Take et al., 1994). The role of
FIG. 7. The cell-surface expression of MK in PHA-activated PBL. (A,
in freshly isolated PBL before (A) and after 3 and 7 days of PHA stimula
Cells were first incubated (30 min at 4°C) in the culture medium with
xpressed nucleolin (Nisole et al., 1999) before washing in PBS and PF
(D) The binding of exogenous MK to PBL. Seven days after PHA activatio
revealing surface nucleolin and MK with specific antibodies (as above
PHA activation, cells were permeabilized by the PFA-Triton procedure
mg/ml). In A to E, the secondary antibodies were the following: horse
antibodies. A cross section for each staining (green for MK and red fo
lymphocytes toward the middle cell layer is presented with the correspo
anti-PTN instead of the anti-MK antibodies were used in these experimthe cell-surface-expressed nucleolin as the MK-binding
protein is under investigation in our laboratory.Inhibition of HIV infection in CEM T-cell clones
expressing MK constitutively
1
C). The cell-surface expression of MK and nucleolin was investigated
and C, respectively) by confocal microscopy (Materials and Methods).
i-nucleolin mAb D3 (20 mg/ml) to cause clustering of the cell-surface-
on. Cells were then incubated with goat anti-MK antibodies (5 mg/ml).
were incubated (30 min at room temperature) with 200 nM MKS before
resence of MK in the nucleoli of PHA-activated PBL. Three days after
incubation of cells with mAb D3 (5 mg/ml) and anti-MK antibodies (2
-red-labeled anti-mouse antibodies and rabbit FITC-labeled anti-goat
olin) is shown with the merge of the two colors in yellow. The scan of
hase contrast. Note. No immunofluorescence was detected when goat
t shown), thus indicating the specific nature of the anti-MK antibodies.B, and
tion (B
the ant
A fixati
n, cells
). (E) P
before
Texas
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257INHIBITION OF HIV ATTACHMENT IN MIDKINE-TREATED CELLSlebaut et al., 1996). These cells were used as parental
ells to establish by stable transfection CEM clones
xpressing MK constitutively. The production of MK in
he different clones was monitored by immunoblotting
sing crude cell extracts in order to select the positive
lones (Fig. 8A). In parallel FACS analysis carried out
n the selected clones for the expression of CD4 and
XCR4 revealed no apparent modification between the
K-producing clones and the corresponding control
EM clones. Furthermore, proliferation of cells was
ot significantly affected in MK-producing CEM
lones, albeit a slightly faster growth rate in CEM/MK
lones compared to the CEM/control clones (not
hown).
Consistent with the anti-HIV effect of the exog-
nously added MK (Figs. 1 to 4), HIV-1 LAI infection
as inhibited in the MK-producing clones MK5, MK7,
nd MK13 compared to the parental CEM cells
CEM/P) and the clone transfected with the plasmid
lone (CEM/C; Fig. 8B). HIV infection was not affected
n the MK14 clone in which MK production was only
aintly detectable (Figs. 8A and B). As for HIV particle
ttachment and entry, there was a strong inhibition in
he MK-producing clones MK7 and MK13 whereas no
ffect occurred in the MK14 clone (Figs. 8C and D).
nterestingly, in the MK7 and MK13 clones the degree
f inhibition of HIV attachment and entry was compa-
able to that occurring in the presence of neutralizing
nti-V3 loop in the parental cells and in the MK-nega-
ive clone MK14 (Figs. 8C and D). The results obtained
ith these MK-producing clones indicate that HIV in-
ection could be inhibited in cells by the endogenously
FIG. 10. The presence of MK on the surface of HeLa P4 cells cocult
HeLa MK21 cells were plated in 8-well glass slides either separately or
temperature) with mAb v4 specific to CD4 (10 mg/ml) and goat anti-M
antibodies were added: horse Texas-red-labeled anti-mouse antibod
staining (green for MK and red for CD4) along with the correspondingroduced MK, as we demonstrated to be the case with
he exogenously added MK.esistance of HIV-permissive cells to infection by
oculturing with MK-producing cells
Parental HeLa cells are not permissive to HIV infection
ue to the lack of CD4 expression. These cells were
sed to establish by transfection CD42 HeLa cell clones
producing MK. Immunoblotting crude HeLa cell extracts
with anti-MK antibodies permitted the selection of sev-
eral HeLa clones (MK8, MK12, MK15, MK17, and MK21)
producing MK (not shown; immunoblotting experiments
similar to that described in Fig. 8A). The production of MK
was also monitored by confocal immunofluorescence
microscopy in the positive clones in which MK was
localized in the nucleolus and abundantly at the cell
surface (not shown, similar to the results observed in
activated PBL described in Figs. 7B and E). No significant
amounts of MK were detectable in the culture superna-
tants of MK-producing cells, thus suggesting that se-
creted MK binds rapidly to its cell-surface receptor.
In order to demonstrate that MK produced by a given
cell can protect a nonproducer bystander cell against
HIV infection, HIV-permissive HeLa-CD4-LTR-lacZ cells
ere cocultured for 24 h with the CD42 HeLa cell clones
producing MK before infection by the HIV-1 LAI isolate
(Fig. 9A). The effector (HeLa/MK cell clones) to target
(HeLa P4 cells) cell ratio was 1:1 and 1:2. At the effector
to target ratio of 1:1, the degree of net inhibition of HIV
infection (after subtracting the background level ob-
served in the presence of AZT) was 75, 61, 86, 84, and
93% with the clones HeLa MK8, MK12, MK15, MK17, and
MK21, respectively. The higher degree of inhibition ob-
served with the clones MK15, MK17, and MK21 was most
probably the consequence of a slightly higher level of MK
ith the MK-producing CD42 HeLa cells. The CD41 HeLa P4 and CD42
eLa P4/HeLa MK21 ratio 1/1 at 24 h before incubation (60 min, at room
bodies (5 mg/ml). Cells were then fixed with PFA and the secondary
rabbit FITC-labeled anti-goat antibodies. A cross section for each
contrast is presented.ured w
at a H
K antiexpression in these clones compared to the clones MK8
and MK12. No apparent inhibitory effect on virus infec-
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258 CALLEBAUT ET AL.tion was observed when the control HeLa/C cells were
used as the effector cells (Fig. 9A). In further experiments
using the HeLa MK17 and MK21 clones, we then dem-
onstrated that such MK-induced anti-HIV LAI resistance
is also effective against other viral isolates, such as
HIV-1 Ba-L and HIV-2 ROD (Fig. 9B). On the other hand,
HIV-1 pseudotyped with MoMLV-envelope glycoproteins
was not affected (Fig. 9B), consistent with the specific
action of MK shown in Fig. 1.
These coculturing experiments of HIV-permissive with
-nonpermissive cells (Fig. 9) suggest that MK produced
by CD42 cells can transmit protection of CD41 bystander
ells against HIV infection. In order to demonstrate that
his latter effect should be the consequence of the ca-
acity of secreted MK from CD42 cells to bind the CD41
bystander cells, HeLa P4 cells were cocultured for 24 h
with the MK-producing HeLa MK21 cells and the expres-
sion of MK and CD4 was monitored by confocal micros-
copy using specific antibodies. The anti-CD4 antibody
FIG. 8. Inhibition of HIV infection in CEM T-cell clones expressing M
cell extracts from the parental CEM cells (CEM/P), the clone transfected
MK5, MK7, MK13, MK14) along with 100 ng of MKS or PTN were anal
anti-MK antibody. The numbers on the left give the position of protein
estimated to be 100 ng/1 3 106 cells. The specificity of the anti-MK an
lack of any reaction with PTN (lanes MK and PTN). (B) Inhibition of HIV
infected with the HIV-1 LAI isolate as described before (Callebaut et al.,
of p24 in the culture supernatant. The figure represents the mean of two
of HIV production in the parental CEM cells. The 100% HIV production
and entry (D) in the MK-producing CEM clones. Experimental conditio
before (Valenzuela et al., 1997), the only difference being that the attac
loop antibody, the HIV-1 LAI preparation was incubated (37°C, 30 min)
nhibition of HIV attachment and entry was calculated considering tha
f triplicate samples is shown.stained the surface of HeLa P4 but not HeLa MK21 cells,
whereas the anti-MK antibody stained the surface ofHeLa-MK21 but not HeLa P4 cells (Fig. 10). In the cocul-
tured cells, the comparison of CD41 staining with the
phase contrast of a given cell monolayer permitted the
differentiation of the HeLa P4 cells from the CD42 HeLa
MK21 cells. Both types of cells proliferated in individual
groups but next to each other, since systematically a
patch of CD41 HeLa P4 cells coexisted with a patch of
D42 HeLa MK21 cells. Interestingly, MK was clearly
detectable on the surface of HeLa P4 cells cocultured
with HeLa MK21 cells (Fig. 10), thus providing evidence
that MK secreted by one cell type has the capacity to
bind neighboring cells.
On the potential role of MK as a cytokine during HIV
infection
Cytokines are important mediators of homeostasis.
They are produced by a variety of cells and act via
membrane receptors on responsive cells. Here we
Expression of recombinant MK in the established CEM clones. Crude
e plasmid alone (CEM/C), and clones selected for MK production (MK4,
y 12.5% SDS/PAGE followed by immunoblotting using a specific goat
s (in kDa). The concentration of MK produced in the MK13 clone was
s was demonstrated by the strong reaction with purified MK and the
ion in the MK-producing CEM clones. The different CEM clones were
nd the virus production was monitored by measuring the concentration
es for each cell type at 5 days postinfection which was during the peak
onded to 760 ng/ml of p24. (C and D) Inhibition of HIV attachment (C)
IV attachment and entry in CEM cells were essentially as described
assay was carried out at 4°C. To demonstrate the effect of the anti-V3
Ab N11/20 (a-V3 at 5 mg/ml) before addition to cells. The percentage
lues obtained in the parental CEM cells were 100%. The mean 6 SDK. (A)
with th
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259INHIBITION OF HIV ATTACHMENT IN MIDKINE-TREATED CELLSleast, in the PBL of healthy individuals. Moreover, in vitro
treatment of lymphocyte by various stimuli induces a
marked increase of MK mRNA expression. Furthermore,
MK becomes readily detectable at the surface of acti-
vated lymphocytes. In view of its various growth factor
effects (Kurtz et al., 1995; Muramatsu, 1994) and its en-
anced expression in response to physiological agents,
long with its specific interaction with target cells, it is
lausible to consider MK as a cytokine that has a poten-
ial function in homeostasis.
The fact that MK is induced by extracellular stimuli
uring events which also result in T-cell activation (Ye
nd Young, 1997) is consistent with the cytokine nature of
K. The cytokine family includes proteins such as inter-
eukins, interferons, and chemokines that mediate sig-
als between cells implicated in the immune system as
ell as other cell populations. The expression of cyto-
ine genes is highly regulated as their transcription be-
omes initiated upon activation and then shuts down
ven in the continuous presence of stimulating agents. In
FIG. 9. MK produced by CD42 cells protects bystander CD41 cells
HeLa P4 cells following coculturing with CD42 MK-producing cells. HIV
producing MK (MK8, MK12, MK15, MK17, MK21) before infection by the
cell ratio was 1:1 and 1:2 as indicated; one amount corresponding to 5 3
eLa cells (HeLa/P) or with the control HeLa/C clone transfected wit
measured in cell extracts directly in order to monitor HIV entry (Nisole e
HeLa/P 2 HIV represent the b-galactosidase activity in the cocultur
HeLa/C 1 AZT represent the cocultures of the control HeLa cell clone
correspond to the background b-galactosidase activity. (B) The MK-me
against infection by HIV-1 pseudotyped with MoMLV-envelope glycopr
each type. After 24 h of coculturing, cells were infected with the X4 HI
in Fig. 1. At 48 h postinfection, the b-galactosidase activity was measu
the absence (HeLa/C) or presence of 5 mM AZT (AZT 1 HeLa/C), and th
HeLa P4 for HIV-1 LAI and HIV-1 MoMLV infection, or HeLa P4-C5 f
percentage HIV production (the abscissa) considering that the value ob
HeLa cells (HeLa/P) and infected with the respective HIV isolate is 10ccord with this, MK expression is induced markedly but
ransiently during T-cell activation of PBL by PHA or
s
dAbs anti-CD3/anti-CD28. Treatment of PBL with IL-2 or
FN-g also results in the induction of MK mRNA, thus
uggesting that these cytokines are potential candidates
esponsible for the induction of MK during the T-cell
ctivation process. Of particular interest is MK induction
n PBL treated with mAb anti-CD28 but not mAb anti-CD3
lone, since for the activation of T lymphocytes the com-
ined signaling of the T-cell receptor-CD3 complex and
he costimulatory CD28 molecule is necessary (Li et al.,
999). The MK induction following engagement of the
D28 receptor alone is most probably the consequence
f IL-2 production. Indeed, the IL-2 enhancer contains a
unctional motif named CD28-response element that
erves as a target for mitogenic T-cell activation signals
Civil et al., 1996). Furthermore, the increased IL-2 pro-
duction is strictly dependent on CD28 costimulation and
does not appear to occur with CD3 stimulation alone (Ott
et al., 1997).
With respect to HIV infection, triggering the CD28
receptor is reported to increase the CD81 cell suppres-
HIV infection. (A) Inhibition of virus infection of HIV-permissive CD41
sive HeLa P4 cells were cocultured for 24 h with the HeLa cell clones
AI isolate. The effector (HeLa/MK cell clones) to target (HeLa P4 cells)
lls. For controls, HeLa P4 cells were cocultured either with the parental
lasmid alone. At 48 h postinfection, the b-galactosidase activity was
99, 2000). The mean 6 SD of triplicate samples is shown. The samples
e parental cells with HeLa P4 cells without infection. The samples
eLa P4 cells infected in the presence of AZT (5 mM), and the values
protection of the bystander cells against HIV infection is not effective
The effector to target ratio was 1:1; corresponding to 5 3 103 cells of
I, R5 HIV-1 Ba-L, X4 HIV-2 ROD, and the HIV-1 MoMLV pseudotype as
above. The effector cells were the control HeLa cell clone infected in
roducing HeLa cell clones MK17 and MK21. The target cells were either
1 Ba-L and HIV-2 ROD infection. The values are represented as the
in the respective coculture of HeLa P4 or P4-C5 cells with the parental
e mean 6 SD of triplicate samples is shown.against
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260 CALLEBAUT ET AL.ingly, HIV replication is inhibited in PBL and macro-
phages which have been treated with IL-2 before HIV
infection (Creson et al., 1999; Kutza et al., 1998; Zhang et
l., 1997). In addition, IL-2 treatment of HIV-infected pa-
ients receiving highly active anti-retroviral therapy re-
ults in a significant increase of CD41 T-lymphocytes
and the failure to isolate HIV from their PBL (Chun et al.,
1999). In such IL-2-treated patients, there is increased
expression of CCR5 and CXCR4 receptors, although the
level of anti-HIV chemokines remains apparently not
affected (Blanco et al., 1999; Zou et al., 1999). The ratio-
nale for the anti-HIV effect of IL-2 in vivo has been
considered to be the consequence of the immune recon-
stitution in HIV-infected individuals (Ghezzi et al., 1997).
owever, the fact that IL-2 is also an efficient inducer of
K that has a direct capacity to inhibit HIV infection
uggests that MK might contribute in part in the benefi-
ial effect observed following IL-2 treatment.
Cytokines through an autocrine or a paracrine way
lay a crucial role in HIV pathogenesis (Pantaleo et al.,
993). Indeed, cytokines can directly or indirectly affect
IV disease progression by modulating the immune sys-
em on the one hand and by regulating virus infection on
he other hand (Manetti et al., 1996). Here we demon-
trated that MK-treated cells are protected against infec-
ion by both T-lymphocyte- and macrophage-tropic HIV
solates. Our results also illustrate that MK-producing
D41 cells are protected against HIV infection while
MK-producing CD42 cells can provide a protection to the
nonproducer CD41 bystander cells. In view of the potent
anti-HIV action of MK, its in vivo expression in blood
lymphocytes and the marked in vitro induction in re-
sponse to physiological stimuli, it is plausible to suggest
that MK is a cytokine that could regulate HIV infection in
an autocrine and paracrine manner and thus be impli-
cated in the evolution of HIV disease. In this respect, the
potential contribution of MK in HIV pathogenesis needs
to be defined along with previously described cytokines
modulating the outcome of HIV infection.
MATERIALS AND METHODS
Materials
Two different human MK preparations were used: syn-
thetic MK (referred to as MKS) corresponding to the last
121 amino acids (i.e., without its potential signal peptide)
was purchased from Peninsula Laboratories Europe Ltd.,
England; the recombinant MK produced in Escherichia
coli (referred to as MKB) was purchased from R & D
ystems. Recombinant human pleiotrophin produced by
he baculovirus expression system, human g-IFN (sp act
3 107 units/mg), and IL-2 produced in E. coli expres-
sion system were purchased from R & D Systems. The
fibroblast growth factor 2 produced in E. coli was from
3igma. MK was iodinated (2.2 3 10 mCi/mmol) using the
olton-Hunter reagent (DuPont, NEN) by a procedure as
w
tecommended by the manufacturer. The synthesis of the
B-19 pseudopeptide, 5[Kc(CH2N)PR]-TASP; and the
control peptides CP-1, Kc(CH2N)PR and HBP8-I: 5[KPR]-
TASP/aM (with a modified template); and the TW70 cy-
lic peptide (RRWCYRKDKPYRKCR) were as described
before (Callebaut et al., 1998a; Nisole et al., 1999, 2000).
Antibodies
The monoclonal antibody (mAb) D3 specific for human
nucleolin was kindly provided by Dr. J. S. Deng, Depart-
ment of Veterans Affair, Medical Center, Pittsburgh,
Pennsylvania (Deng et al., 1996). mAb CBT4 specific to
human CD4 and reacting with the gp120-binding domain
(Valenzuela et al., 1997) was provided by Dr. E. Bosmans
(clone CB-T4-2; Eurogenetics, Tessenderlo, Belgium).
mAb v4 (clone L120) recognizing amino acids 306–370
(corresponding to the 4th immunoglobulin superfamily
domain, IgSF) of the human CD4 was purchased from
Becton-Dickinson (Mountain View, CA). mAb N11/20 di-
rected against the V3 loop of HIV-1 LAI isolate was
provided by Dr. J. C. Mazie, Hybridolab, Institut Pasteur,
Paris. mAb 110-4 against HIV-1 LAI V3 loop was the
generous gift of the Genetic Systems. Goat anti-human
MK (raised against the E. coli-derived MK) and PTN
(raised against a baculovirus generated PTN) antibodies
were purchased from R & D Systems. FITC-labeled goat
anti-mouse IgG and rabbit anti-Goat IgG were from
Sigma, whereas Texas red dye-conjugated horse anti-
mouse IgG was from Valbiotech, Paris. The mAbs
against CD3 (IgG2a) and CD28 (IgG1) were purchased
from Immunotech, Marseille, France. The mAbs specific
to human CXCR4 and CCR5 were obtained through the
AIDS Research and Reference Reagent Program, AIDS
Program, NIAID, NIH; CXCR4 mAb 12G5 from Dr. J. Hoxie;
CCR5 mAbs 12D1 from Dr. S. Peiper; and 2D7 from
LeukoSite, Inc.
Cell lines and virus preparations
CEM (clone 13) and MT-4 cells were propagated in
RPMI 1640 (Bio-Whittaker, Verviers, Belgium). Human
HeLa-CD4-LTR-LacZ expressing or not expressing CCR5
were referred to as HeLa P4-C5 and HeLa P4, respec-
tively. These HeLa cells (provided by Drs. P. Charneau
and O. Schwartz; Institut Pasteur, Paris) were cultured in
Dulbecco’s modified Eagle’s medium (Gibco) supple-
mented with G418 sulfate (500 mg/ml) for the HeLa P4
ells and with G418 sulfate (500 mg/ml)/hygromycin B
300 mg/ml) for the HeLa P4-C5 cells (Calbiochem-Nova-
iochem Corp., La Jolla, CA) (Nisole et al., 2000). All cells
ere cultured with 10% (v/v) heat-inactivated (56°C, 30
in) fetal calf serum (FCS; Boehringer Mannheim GmbH,
ermany) and 50 IU/ml penicillin-steptomycin (Gibco,
RL). Peripheral blood lymphocytes from healthy donors
ere prepared by Ficoll-Hypaque density gradient cen-
rifugation and suspended in RPMI 1640 medium con-
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261INHIBITION OF HIV ATTACHMENT IN MIDKINE-TREATED CELLStaining 10% fetal calf serum (Callebaut et al., 1996). PBL
were stimulated with phytohemagglutinin (PHA; 10 ng/
ml) and cultured for 3 days, and then the culture medium
was replaced by fresh medium containing 10% (v/v) T-cell
growth factor (TCGF; Biotest). The X4 HIV-1 LAI and HIV-2
ROD were as described before (Callebaut et al., 1996).
he R5 HIV-1 Ba-L, JR-CSF, ADA, and the primary syncy-
ium-inducing HIV-1 UGO29A and non-syncytium-induc-
ng HIV-1 BRO25C isolates were provided by the AIDS
esearch and Reference Reagent Program (AIDS Pro-
ram, NIAID, NIH) and were used as described before
Callebaut et al., 1996; Nisole et al., 2000). Different
iruses were propagated in CEM cells or in PBL as
equired. The HIV-1 pseudotyped with VSV-envelope gly-
oproteins was kindly provided by Dr. O. Schwartz (Insti-
ut Pasteur, Paris). The HIV-1 pseudotyped with MoMLV-
nvelope glycoproteins was as described before (Calle-
aut et al., 1998a). The amount of each virus preparation
was estimated by measuring the multiplicity of virus
infection (MOI) and aliquots of virus stocks were stored
at 2135°C. For different infections of HeLa P4 and P4-C5
cells, the MOI of various HIV-1 isolates was 1. For the
assay of HIV attachment to cells, the virus preparations
were centrifuged (100,000 g, for 30 min at 4°C) in order
to concentrate HIV and separate it from any soluble p24
or gp120 (Laurent et al., 1989). The viral pellet was
uspended in culture medium and filtered through
.22-mm pore size filters (Millipore) in order to eliminate
ggregates. Such HIV preparations generated concen-
rated virus that is highly infectious and was used for the
ttachment experiments at MOI 3. The 50% inhibitory
oncentration (IC50) value of HB-19 on HIV infection was
ssayed both in the HeLa P4 and HeLa P4-C5 cells and
n PHA-activated PBL as reported before (Callebaut et al.,
996; Nisole et al., 2000).
Assay of HIV particle attachment and entry
The attachment of HIV to cells was monitored after 1 h
of incubation at 4°C. The attachment assay was carried
out at 4°C or at room temperature (20°C) in order to
block viral entry (Krust et al., 1993) and potential HIV
endocytosis (Mare´chal et al., 1998). Cells were then
washed extensively with culture medium containing 10%
FCS to eliminate unbound HIV particles, and the amount
of p24 associated with cells was measured in cell ex-
tracts as an estimate for the amount of HIV attachment
by p24 Core Profile enzyme-linked immunosorbent assay
(DuPont). In order to demonstrate that most of the HIV
associated with cells represented virus particles bound
on the surface of cells, samples of cells incubated with
virus were washed with PBS (containing I mM EDTA)
before treatment with trypsin to eliminate virus bound on
the cell surface as described before (Nisole et al., 2000).Evidence that the virus attachment was mediated by the
HIV-envelope glycoprotein gp120 was provided by the
capacity of anti-V3 loop mAbs N11/20 or 110/4 to inhibit
the attachment process (Valenzuela et al., 1997). HIV
entry was monitored by measuring the concentration of
intracellular p24 as described before (Krust et al., 1993;
Valenzuela et al., 1997). For this purpose, cells were
incubated with HIV for 1 h at 37°C, before washing and
trypsinization to remove HIV still bound on the cell sur-
face. The amount of p24 was then measured in cell
extracts as an estimate for the amount of intracellular
HIV. Nucleus-free cell extracts for the attachment and
entry assays were prepared as described before (Valen-
zuela et al., 1997). Under our experimental conditions,
HIV entry during a 1-h incubation at 37°C was inhibited
by .95% in the presence of neutralizing antibodies
against either CD4 (mAb CBT4) or the V3 loop (mAbs
N11/20, 110/4).
Confocal microscopy
Laser scanning confocal immunofluorescence mi-
croscopy (Leica TCS4D) was carried out by fixing cells
either with parafolmaldehyde (PFA; 3.7%) for mem-
brane and cytoplasmic staining or with parafolmalde-
hyde/Triton X-100 solution (PFA/Triton) for intracellular
staining (including nucleus) as previously described
(Nisole et al., 2000). Cells plated in 8-well glass slides
(Lab-Tek Brand, Nalge Nunc International, Naperville,
IL) were incubated with antibodies for the clustering of
cell-surface-expressed proteins before fixation with
PFA (for cell-surface labeling) or PFA/Triton (for per-
meabilization of the nuclear membrane). For immuno-
fluorescence analysis of cells in suspension, PBL
were added to slides which were precoated with poly-
L-lysine at 30 mg/ml (Sigma) and left for 15 min before
ashing the attached cells with PBS and proceeding
ith the experimental protocol.
he binding of the 125I-labeled MK to cells
HeLa P4 cells preincubated (37°C, 15 min) with the
ifferent reagents were further incubated at room tem-
erature (30 min) with 80 nM of 125I-labeled MK in culture
edium containing 10% FCS. Cells were then washed
xtensively with the culture medium before preparation
f nuclear free cell extracts in lysis buffer: 20 mM Tris
Cl, pH 7.6, 150 mM NaCl, 5 mM MgCl2, 0.2 mM phe-
nylmethylsulfonyl fluoride, 5 mM b-mercaptoethanol,
aprotinin (1000 U/ml), and 0.5% Triton X-100. Aliquots
were then analyzed by SDS/PAGE or counted to evaluate
125the amount of MK binding. The level of the I-labeled
MK band observed in SDS/PAGE was systematically
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262 CALLEBAUT ET AL.correlated with the amount of the radioactivity estimated
by counting using an automatic gamma counter (Model
1272 Clinigamma, Wallac, Turku, Finland).
Establishment of CEM and HeLa cell clones
expressing MK
An oligo(dT)-primed cDNA preparation was obtained us-
ing total RNA from human placenta (gift of Dominique Re-
bouillat, Institut Pasteur). The full-length cDNA (432 nucle-
otides) encoding the precursor MK (with the peptide signal
domain) was obtained by PCR amplification using the prim-
ers mkF and mkR containing the BamHI and XbaI restriction
sequence, respectively, mkF 1, 59-GGATTCAGGATGCAG-
ACCGAGGCTTCCTCC-39; and mkR 2, 59-TCTAGACTA-
TCCTTTCCCTTCCCTTTCTTG-39.
This cDNA was cloned in pCR 2.1 TOPO (Invitrogen)
y TA cloning before the insertion of the MK cDNA in
he plasmid pNeoSRaIII (Callebaut et al., 1998b) at the
amHI/XbaI restriction sites. CEM and HeLa cells
ere transfected with the MK-expressing plasmid by
lectroporation and were selected by culturing in me-
ium containing G418 under experimental conditions
s described before (Callebaut et al., 1998b). Control
EM and HeLa cell clones were established by trans-
ection with the parental plasmid pNeoSRaIII. The
ontrol and the MK-producing cell clones were ana-
yzed by FACS analysis for the expression of CD4,
XCR4, and nucleolin as previously described (Calle-
aut et al., 1998a; Nisole et al., 1999). The expression
f MK in the clones was monitored by immunoblotting
sing crude cell extracts (material corresponding to
hat from 5 3 105 cells) and goat anti-human MK
ntibodies (1 mg/ml). The secondary antibody was
abbit anti-goat horseradish peroxidase-labeled immu-
oglobulins (Amersham Pharmacia Biotech.).
etection of MK mRNA expression
The expression of MK mRNA was investigated by
everse transcription-polymerase chain reaction (RT-
CR). Total RNA was prepared from PBL (2 3 107) with
NA-Plus (Quantum Biotechnologies, France) according
o the manufacturer’s instructions. RT was carried out
ith oligo(dT) and 1–2 mg of total RNA using Superscript
II RNase H2 reverse transcriptase (Gibco BRL). PCR was
performed in a RoboCycler 96 (Stratagene) with specific
primers for MK to amplify its full-length coding sequence
including the peptide signal domain: mk07 1, 59-ATG-
CAGCACCGAGGCTTCCTCCTCC-39; mk08 2, 59-CTAG-
TCCTTTCCCTTCCCTTTCTTGGC-39.
For controls, RT-PCR was also performed to detect
GAPDH, IFN-g, PTN, and nucleolin. The specific primers
for these latter were the following:
CGAPDH gapdh 1, 59-TGAAGGTCGGAGTCAACGGAT-
TTGGT-39;
gapdh 2, 59-CATGTGGGCCATGAGGTCCAC-
CAC-39;
IFN-g ifn5 1, 59-ATGAAATATACAAGTTATATC-39;
ifn3 2, 59-GCGACAGTTCAGCCATCACTT-39;
PTN ptnF2 1, 59-TGTGGAGAATGGCAGTGGAGT-
GTG-39;
ptnR2 2, 59-TAATCCAGCATCTTCTCCTG-39;
ucleolin p95F4 1, 59-TTGAATTCATCATGGTGAAGCT-
CGCGAAGGC-39;
p95R2 2, 59-TAGGGCCCAGGCTCTTCCTC-
CTC-39.
PCR amplification conditions were optimized for each
primer; MK: 95°C for 2 min, 40 cycles of 95°C for 30 s,
60°C for 30 s, and 72°C for 30 s, and 72°C for 5 min;
GAPDH and nucleolin: 95°C for 2 min, 30 cycles of 95°C
for 30 s, 60°C for 30 s, and 72°C for 45 s, and 72°C for
5 min; PTN and IFN-g: 95°C for 2 min, 40 cycles of 95°C
for 30 s, 57°C for 30 s, and 72°C for 30 s, and 72°C for
5 min. The size of RT-PCR product for MK, GAPDH, IFN-g,
TN, and nucleolin was 432, 983, 433, 368, and 835 bp,
espectively.
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